Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Pharmacogenet Genomics. 2009 Dec;19(12):965–971. doi: 10.1097/FPC.0b013e3283333b80

Figure 2.

Figure 2

Trial simulation results similar to those in Fig. 1, except CYP2C9 variants in the PGx-based initiation of therapy arm received double the predicted maintenance dose days 1-2 and no dose adjustment for the first 18 days. See text and Fig. 1 for further details.